Home > Insider Trading > Filing (0001415889-21-000623)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1733294	Generation Bio Co.	GBIO	Pharmaceutical Preparations (2834)	814301281

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1814189	Douglas Kerr	C/O Generation Bio Co., 301 Binney St Cambridge MA 02142	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-08	11,267	$4.59	337,825	No	4	M	Direct
Common Stock	Disposition	2021-02-08	7,500	$33.01	330,325	No	4	S	Direct
Common Stock	Disposition	2021-02-08	3,767	$34.08	326,558	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-02-08	11,267	$0.00	11,267	$4.59

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
101,226		2028-04-01	No	4	M	Direct

Footnotes

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.52 to $33.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.60, inclusive.
The option to purchase 123,760 shares of common stock was granted on April 2, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on April 2, 2019 and the remaining shares vesting in equal quarterly installments thereafter.